Song Luo1, Lijuan Yang2, Chun Wang1, Chuanmiao Liu3, Dianming Li4. 1. Department of Neurology, the First Affiliated Hospital of Bengbu Medical College, Bengbu 233004, Anhui Province, China. 2. Department of Pediatrics, the First Affiliated Hospital of Bengbu Medical College, Bengbu 233004, Anhui Province, China. 3. Department of Infectious Diseases, the First Affiliated Hospital of Bengbu Medical College, Bengbu 233004, Anhui Province, China. 4. Department of Respiratory Medicine, the First Affiliated Hospital of Bengbu Medical College, Bengbu 233004, Anhui Province, China.
Abstract
OBJECTIVE: To observe the clinical effect of plasma exchange and tocilizumab in treatment of patients with severe coronavirus disease 2019 (COVID-19). METHODS: Six patients with severe COVID-19 admitted in First Affiliated Hospital of Bengbu Medical College from January 25 to February 25, 2020. Three patients were treated with plasma exchange and three patients were treated with tocilizumab. The effect on excessive inflammatory reaction of plasma exchange and tocilizumab was observed. RESULTS: The C-reactive protein (CRP) and IL-6 levels were significantly decreased and the lymphocyte and prothrombin time were improved in 3 patients after treatment with plasma exchange; while inflammation level was not significantly decreased, and lymphocyte and prothrombin time did not improve in 3 patients treated with tocilizumab. CONCLUSIONS: For severe COVID-19 patients with strong inflammatory reaction, plasma exchange may be preferred.
OBJECTIVE: To observe the clinical effect of plasma exchange and tocilizumab in treatment of patients with severe coronavirus disease 2019 (COVID-19). METHODS: Six patients with severe COVID-19 admitted in First Affiliated Hospital of Bengbu Medical College from January 25 to February 25, 2020. Three patients were treated with plasma exchange and three patients were treated with tocilizumab. The effect on excessive inflammatory reaction of plasma exchange and tocilizumab was observed. RESULTS: The C-reactive protein (CRP) and IL-6 levels were significantly decreased and the lymphocyte and prothrombin time were improved in 3 patients after treatment with plasma exchange; while inflammation level was not significantly decreased, and lymphocyte and prothrombin time did not improve in 3 patients treated with tocilizumab. CONCLUSIONS: For severe COVID-19 patients with strong inflammatory reaction, plasma exchange may be preferred.
Authors: Jackie L Nam; Kaoru Takase-Minegishi; Sofia Ramiro; Katerina Chatzidionysiou; Josef S Smolen; Désirée van der Heijde; Johannes W Bijlsma; Gerd R Burmester; Maxime Dougados; Marieke Scholte-Voshaar; Ronald van Vollenhoven; Robert Landewé Journal: Ann Rheum Dis Date: 2017-03-10 Impact factor: 19.103
Authors: L He; Y Ding; Q Zhang; X Che; Y He; H Shen; H Wang; Z Li; L Zhao; J Geng; Y Deng; L Yang; J Li; J Cai; L Qiu; K Wen; X Xu; S Jiang Journal: J Pathol Date: 2006-11 Impact factor: 7.996
Authors: Gopal K Patidar; Kevin J Land; Hans Vrielink; Naomi Rahimi-Levene; Eldad J Dann; Hind Al-Humaidan; Steven L Spitalnik; Yashaswi Dhiman; Cynthia So-Osman; Salwa I Hindawi Journal: Vox Sang Date: 2021-03-17 Impact factor: 2.996
Authors: Seena Tabibi; Tara Tabibi; Rosalynn R Z Conic; Nassim Banisaeed; Michael B Streiff Journal: J Intensive Care Med Date: 2020-07-15 Impact factor: 3.510